Missing Script

Get updates

Evidence Explorer · MS-N255 · Mind–body and psychological support · quality of life versus cancer survival · Appraised November 6, 2026

Supportive-expressive group therapy can improve mood, pain or social functioning for some women with metastatic breast cancer, but two substantial randomized trials did not show that it prolongs survival.

Evidence at a glance

  • Benefit signal: Supportive-care benefits are plausible; a survival benefit was not demonstrated.
  • Certainty: Moderate for no large survival effect in these trials; symptom effects vary by population and baseline distress.
  • Risk context: Group therapy is generally low physical risk, but fit, privacy, emotional activation and access to urgent mental-health care matter.
  • Cancer-control relevance: Direct cancer-control question: the trials do not support presenting group therapy as a survival-prolonging cancer treatment.

What was studied

A Canadian randomized trial assigned 235 women with metastatic breast cancer to weekly 90-minute supportive-expressive group therapy plus usual care (158) or usual care alone (77). Survival was the primary outcome.

An independent randomized trial assigned 227 women to supportive-expressive group therapy (147) or an active relaxation control (80), providing a second direct test of the survival claim.

What the study found

In the Canadian trial, median survival was 17.9 versus 17.6 months. The unadjusted hazard ratio was 1.06 (95% CI 0.78 to 1.45); the adjusted estimate was 1.23 (95% CI 0.88 to 1.72). Mood and pain improved, especially among participants with greater baseline distress.

In the independent trial, median survival was 24.0 versus 18.3 months, but the difference was not statistically reliable: unadjusted HR 0.92 (95% CI 0.69 to 1.26) and adjusted HR 1.06 (95% CI 0.74 to 1.51). Depression, hopelessness and social functioning improved.

What this does not establish

A nonsignificant result does not prove the hazard ratio is exactly 1, but these trials exclude a large, dependable survival effect. Multiple reports from one trial should not be counted as independent evidence.

A new 2026 meta-analysis of 24 psychosocial-intervention trials found a small pooled association with overall survival (summary HR 0.87, 95% CI 0.77 to 0.99; I²=45%). Heterogeneity, mixed interventions and derived hazard ratios mean that pooled result does not reverse these direct null trials or prove that supportive-expressive therapy treats cancer.

Safety and practical context

Therapy should be offered for coping, connection and symptom support—not as a condition for survival or as evidence that attitude controls cancer.

Groups need confidentiality, skilled facilitation and a pathway for suicidality, severe depression, trauma reactions or uncontrolled symptoms.

Questions for the care team

  • Is the goal emotional support, pain coping or social connection rather than tumor control?
  • Would individual therapy, a group or another support format fit better?
  • Is anyone implying that survival depends on positive thinking or group attendance?

Sources and identifiers

Funding and conflicts: Funding and conflict disclosures vary by trial and were not fully verified from all accessible reports.

Source access and dates: Primary trial abstracts and the new meta-analysis abstract were appraised; complete historical full texts were not all independently verified. Sources checked November 6, 2026. Last literature search November 6, 2026.

Educational evidence summary, not individualized medical advice. Psychological and sleep interventions should complement—not replace—oncology, palliative, mental-health or sleep-medicine care.